Toggle Main Menu Toggle Search

Open Access padlockePrints

Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Lookup NU author(s): Dr Yvette DrewORCiD



This is the authors' accepted manuscript of an article that has been published in its final definitive form by American Association for Cancer Research, 2020.

For re-use rights please refer to the publisher's terms and conditions.


©2019 American Association for Cancer Research.PURPOSE: Tissue factor (TF) is a potential target in cervical cancer, as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody-drug conjugate targeting TF, has demonstrated encouraging activity in solid tumors. Here we report data from the cervical cancer cohort of innovaTV 201 phase I/II study (NCT02001623). PATIENTS AND METHODS: Patients with recurrent or metastatic cervical cancer received tisotumab vedotin 2.0 mg/kg every 3 weeks until progressive disease, unacceptable toxicity, or consent withdrawal. The primary objective was safety and tolerability. Secondary objectives included antitumor activity. RESULTS: Of the 55 patients, 51% had received ≥2 prior lines of treatment in the recurrent or metastatic setting; 67% had prior bevacizumab + doublet chemotherapy. Fifty-one percent of patients had squamous cell carcinoma. The most common grade 3/4 treatment-emergent adverse events (AEs) were anemia (11%), fatigue (9%), and vomiting (7%). No grade 5 treatment-related AEs occurred. Investigator-assessed confirmed objective response rate (ORR) was 24% [95% confidence interval (CI): 13%-37%]. Median duration of response (DOR) was 4.2 months (range: 1.0+-9.7); four patients responded for >8 months. The 6-month progression-free survival (PFS) rate was 29% (95% CI: 17%-43%). Independent review outcomes were comparable, with confirmed ORR of 22% (95% CI: 12%-35%), median DOR of 6.0 months (range: 1.0+-9.7), and 6-month PFS rate of 40% (95% CI: 24%-55%). Tissue factor expression was confirmed in most patients; no significant association with response was observed. CONCLUSIONS: Tisotumab vedotin demonstrated a manageable safety profile and encouraging antitumor activity in patients with previously treated recurrent or metastatic cervical cancer.

Publication metadata

Author(s): Hong DS, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau H-T, Machiels J-P, Spicer JF, Jones R, Forster MD, Cornez N, Gennigens C, Johnson ML, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN, Coleman RL

Publication type: Article

Publication status: Published

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Year: 2020

Volume: 26

Issue: 6

Pages: 1220-1228

Print publication date: 15/03/2020

Online publication date: 03/12/2019

Acceptance date: 26/11/2019

Date deposited: 18/04/2020

ISSN (print): 1078-0432

ISSN (electronic): 1557-3265

Publisher: American Association for Cancer Research


DOI: 10.1158/1078-0432.CCR-19-2962

PubMed id: 31796521


Altmetrics provided by Altmetric